BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

498 related articles for article (PubMed ID: 21664647)

  • 1. Intratumoral budding as a potential parameter of tumor progression in mismatch repair-proficient and mismatch repair-deficient colorectal cancer patients.
    Lugli A; Vlajnic T; Giger O; Karamitopoulou E; Patsouris ES; Peros G; Terracciano LM; Zlobec I
    Hum Pathol; 2011 Dec; 42(12):1833-40. PubMed ID: 21664647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Node-negative colorectal cancer at high risk of distant metastasis identified by combined analysis of lymph node status, vascular invasion, and Raf-1 kinase inhibitor protein expression.
    Zlobec I; Baker K; Minoo P; Jass JR; Terracciano L; Lugli A
    Clin Cancer Res; 2008 Jan; 14(1):143-8. PubMed ID: 18172264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epithelial-mesenchymal transition (EMT) protein expression in a cohort of stage II colorectal cancer patients with characterized tumor budding and mismatch repair protein status.
    Kevans D; Wang LM; Sheahan K; Hyland J; O'Donoghue D; Mulcahy H; O'Sullivan J
    Int J Surg Pathol; 2011 Dec; 19(6):751-60. PubMed ID: 21791486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urokinase-type plasminogen activator is a marker of aggressive phenotype and an independent prognostic factor in mismatch repair-proficient colorectal cancer.
    Minoo P; Baker K; Baumhoer D; Terracciano L; Lugli A; Zlobec I
    Hum Pathol; 2010 Jan; 41(1):70-8. PubMed ID: 19740518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of APAF-1, E-cadherin and peritumoral lymphocytic infiltration in tumour budding in colorectal cancer.
    Zlobec I; Lugli A; Baker K; Roth S; Minoo P; Hayashi S; Terracciano L; Jass JR
    J Pathol; 2007 Jul; 212(3):260-8. PubMed ID: 17516584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor Budding and PDC Grade Are Stage Independent Predictors of Clinical Outcome in Mismatch Repair Deficient Colorectal Cancer.
    Ryan É; Khaw YL; Creavin B; Geraghty R; Ryan EJ; Gibbons D; Hanly A; Martin ST; O'Connell PR; Winter DC; Sheahan K
    Am J Surg Pathol; 2018 Jan; 42(1):60-68. PubMed ID: 29112018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of RHAMM within the hierarchy of well-established prognostic factors in colorectal cancer.
    Zlobec I; Terracciano L; Tornillo L; Günthert U; Vuong T; Jass JR; Lugli A
    Gut; 2008 Oct; 57(10):1413-9. PubMed ID: 18436576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of β-2-microglobulin expression in colorectal cancers stratified by mismatch repair status.
    Koelzer VH; Baker K; Kassahn D; Baumhoer D; Zlobec I
    J Clin Pathol; 2012 Nov; 65(11):996-1002. PubMed ID: 22859396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mismatch repair system and p53 expression in patients with T1 and T2 colorectal cancer: predictive role of lymph node metastasis and survival.
    Huh JW; Kim HC; Kim SH; Park YA; Cho YB; Yun SH; Lee WY; Chun HK
    J Surg Oncol; 2014 Jun; 109(8):848-52. PubMed ID: 24623275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic analysis of proteins from different signaling pathways in the tumor center and the invasive front of colorectal cancer.
    Karamitopoulou E; Zlobec I; Panayiotides I; Patsouris ES; Peros G; Rallis G; Lapas C; Karakitsos P; Terracciano LM; Lugli A
    Hum Pathol; 2011 Dec; 42(12):1888-96. PubMed ID: 21664646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic assessment of protein phenotypes characterizing high-grade tumour budding in mismatch repair-proficient colorectal cancer.
    Karamitopoulou E; Lugli A; Panayiotides I; Karakitsos P; Peros G; Rallis G; Patsouris ES; Terracciano L; Zlobec I
    Histopathology; 2010 Aug; 57(2):233-43. PubMed ID: 20716165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intramural and extramural vascular invasion in colorectal cancer: prognostic significance and quality of pathology reporting.
    Betge J; Pollheimer MJ; Lindtner RA; Kornprat P; Schlemmer A; Rehak P; Vieth M; Hoefler G; Langner C
    Cancer; 2012 Feb; 118(3):628-38. PubMed ID: 21751188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumour budding at invasive margins and outcome in colorectal cancer.
    Kanazawa H; Mitomi H; Nishiyama Y; Kishimoto I; Fukui N; Nakamura T; Watanabe M
    Colorectal Dis; 2008 Jan; 10(1):41-7. PubMed ID: 18078460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metastatic potential in T1 and T2 colorectal cancer.
    Fang WL; Chang SC; Lin JK; Wang HS; Yang SH; Jiang JK; Chen WC; Lin TC
    Hepatogastroenterology; 2005; 52(66):1688-91. PubMed ID: 16334758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor budding is an independent predictor of outcome in AJCC/UICC stage II colorectal cancer.
    Betge J; Kornprat P; Pollheimer MJ; Lindtner RA; Schlemmer A; Rehak P; Vieth M; Langner C
    Ann Surg Oncol; 2012 Nov; 19(12):3706-12. PubMed ID: 22669453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathologic prognostic factors in Barrett's associated adenocarcinoma: a follow-up study of 96 patients.
    Torres C; Turner JR; Wang HH; Richards W; Sugarbaker D; Shahsafaei A; Odze RD
    Cancer; 1999 Feb; 85(3):520-8. PubMed ID: 10091725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of cell cycle and apoptosis regulatory proteins in mismatch repair-proficient colorectal cancer: a tissue microarray-based approach.
    Tornillo L; Lugli A; Zlobec I; Willi N; Glatz K; Lehmann F; Spichtin HP; Maurer R; Stoios D; Sauter G; Terracciano L
    Am J Clin Pathol; 2007 Jan; 127(1):114-23. PubMed ID: 17145638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumour budding is a strong and independent prognostic factor in pancreatic cancer.
    Karamitopoulou E; Zlobec I; Born D; Kondi-Pafiti A; Lykoudis P; Mellou A; Gennatas K; Gloor B; Lugli A
    Eur J Cancer; 2013 Mar; 49(5):1032-9. PubMed ID: 23177090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Local recurrence in mismatch repair-proficient colon cancer predicted by an infiltrative tumor border and lack of CD8+ tumor-infiltrating lymphocytes.
    Zlobec I; Terracciano LM; Lugli A
    Clin Cancer Res; 2008 Jun; 14(12):3792-7. PubMed ID: 18559598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of p16 in lymph node metastases of adjuvantly treated stage III colorectal cancer patients identifies poor prognostic subgroups: a retrospective analysis of biomarkers in matched primary tumor and lymph node metastases.
    Karamitopoulou E; Zlobec I; Koumarianou A; Patsouris ES; Peros G; Lugli A
    Cancer; 2010 Oct; 116(19):4474-86. PubMed ID: 20572035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.